MCID: ANX010
MIFTS: 73

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 58 12 30 6 44 41 17 74
Anxiety Disorders 56 45 74
Anxiety Disorder 12 15 17
Anxiety State 12 74
Anxiety Neurosis 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2030
OMIM 58 607834
MeSH 45 D001008
NCIt 51 C2878
SNOMED-CT 69 65673007
ICD10 34 F41.8 F41.9
MedGen 43 C0003467

Summaries for Anxiety

OMIM : 58 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and phobic disorder, and has symptoms including agitation, sleeplessness and mental and behavioral signs and symptoms. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Sodium Citrate and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

MedlinePlus : 44 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Wikipedia : 77 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 34.4 BDNF COMT CRHR1 HTR1A HTR2A MAOA
2 phobic disorder 33.7 COMT HTR1A MAOA SLC6A4
3 social phobia 33.7 HTR1A MAOA SLC6A4
4 panic disorder 33.3 CCKBR COMT CRH HTR1A HTR2A MAOA
5 agoraphobia 33.1 CCKBR HTR1A MAOA SLC6A4
6 phobia, specific 32.7 COMT MAOA
7 avoidant personality disorder 32.5 MAOA SLC6A4 TPH1
8 fibromyalgia 32.5 COMT CRH HTR2A SLC6A4
9 irritable bowel syndrome 32.4 CRH CRHR1 SLC6A4 TPH1
10 autism spectrum disorder 32.4 BDNF HTR2A SLC6A4 TPH2
11 eating disorder 32.4 BDNF CNR1 COMT CRH HTR2C SLC6A4
12 bipolar disorder 32.4 BDNF COMT HTR1A HTR2A SLC6A4 TPH1
13 bulimia nervosa 32.4 BDNF COMT HTR2A SLC6A4
14 postpartum depression 32.4 BDNF COMT CRH MAOA SLC6A4
15 migraine with or without aura 1 32.2 CNR1 COMT HTR1A HTR2A HTR2C MAOA
16 obsessive-compulsive disorder 32.2 BDNF COMT CRH CYP2D6 HTR1A HTR2A
17 post-traumatic stress disorder 32.2 BDNF CNR1 COMT CRH HTR2A MAOA
18 parkinson disease, late-onset 32.0 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
19 schizophrenia 31.8 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
20 depression 31.7 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
21 alexithymia 31.3 COMT HTR1A SLC6A4
22 pain - chronic 31.2 COMT NR3C1
23 personality disorder 31.1 BDNF COMT HTR1A HTR2A HTR2C MAOA
24 anorexia nervosa 31.0 BDNF COMT CRH HTR2A SLC6A4
25 alcohol abuse 30.9 BDNF CNR1 HTR2A SLC6A4
26 substance abuse 30.8 BDNF COMT CYP2D6 MAOA SLC6A4
27 conduct disorder 30.8 COMT MAOA SLC6A4 TPH1
28 dysthymic disorder 30.7 HTR2A MAOA SLC6A4
29 oppositional defiant disorder 30.7 COMT MAOA SLC6A4 TPH2
30 tobacco addiction 30.7 COMT HTR2A MAOA SLC6A4 TPH1
31 disease of mental health 30.6 BDNF CNR1 COMT CRH CYP2D6 HTR1A
32 premature ejaculation 30.6 HTR1A HTR2C SLC6A4
33 mood disorder 30.6 BDNF COMT CRH CRHR1 HTR1A HTR2A
34 attention deficit-hyperactivity disorder 30.6 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
35 antisocial personality disorder 30.5 COMT MAOA SLC6A4
36 major depressive disorder 30.5 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
37 bipolar i disorder 30.4 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
38 alcohol dependence 30.4 BDNF CNR1 COMT CRHR1 HTR1A HTR2A
39 amnestic disorder 30.4 BDNF CNR1 HTR1A
40 drug dependence 30.4 BDNF CNR1 CRH OPRL1 SLC6A4
41 pathological gambling 30.3 HTR2A MAOA SLC6A4
42 schizoaffective disorder 30.3 BDNF COMT HTR2A SLC6A4
43 mental depression 30.3 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
44 chronic fatigue syndrome 30.2 COMT CRH HTR1A HTR2A MAOA NR3C1
45 borderline personality disorder 30.2 BDNF COMT HTR1A HTR2A HTR2C MAOA
46 psychotic disorder 30.2 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
47 atypical depressive disorder 30.2 CRH HTR2A MAOA SLC6A4
48 substance dependence 30.1 BDNF CNR1 CYP2D6 MAOA SLC6A4
49 endogenous depression 30.0 BDNF CRH CRHR1 HTR1A HTR2A MAOA
50 paranoid schizophrenia 29.9 BDNF COMT HTR2A MAOA SLC6A4 TPH2

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 80)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Conn's Syndrome
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia, Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


agitation, sleeplessness, mental and behavioral signs and symptoms, nervousness, feeling tense, feeling jittery, anxiety symptoms

MGI Mouse Phenotypes related to Anxiety:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 BDNF CCKBR CNR1 COMT CRH CRHR1
2 homeostasis/metabolism MP:0005376 10.21 BDNF CCKBR CNR1 COMT CRH CRHR1
3 nervous system MP:0003631 10.1 BDNF CCKBR CNR1 COMT CRH CRHR1
4 cardiovascular system MP:0005385 10.06 CCKBR COMT CRHR1 HTR1A MAOA NR3C1
5 integument MP:0010771 10.02 BDNF CCKBR CNR1 CRH HTR2C NR3C1
6 adipose tissue MP:0005375 9.93 CNR1 CRH HTR2C NR3C1 TPH1 TPH2
7 no phenotypic analysis MP:0003012 9.7 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
8 normal MP:0002873 9.56 BDNF CNR1 CRH CRHR1 NR3C1 OPRL1
9 respiratory system MP:0005388 9.17 BDNF COMT CRH CRHR1 NR3C1 TPH1

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1288)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 68-04-2
2
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
3
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 28981-97-7 2118
4
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 99-66-1 3121
5
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
6
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2 508233-74-7 9966051
7
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10024-97-2 948
8
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59467-70-8 4192
9
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6740-88-1 3821
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
11
Buspirone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36505-84-7 2477
12
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
14
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
15
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
16
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
17
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
18
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 54739-18-3 3404 5324346
19
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
20
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
21
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
22
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
23
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290
24
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
25
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
26
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 27203-92-5 33741
27
Rabeprazole Approved, Investigational Phase 4,Not Applicable 117976-89-3 5029
28
Trimebutine Approved Phase 4 39133-31-8
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 437-38-7 3345
30
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 439-14-5 3016
31
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
32
Amoxicillin Approved, Vet_approved Phase 4,Early Phase 1 26787-78-0 33613
33
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1972-08-3 16078
34
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
35
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-03-3
36
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
37
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
38
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
39
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 50-28-2 5757
40
Drospirenone Approved Phase 4 67392-87-4 68873
41
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 28014-46-2
42
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
43
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113-45-1 4158
44
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
45
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
46
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
47
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 60142-96-3 3446
48
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
49
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
50
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61337-67-5, 85650-52-8 4205

Interventional clinical trials:

(show top 50) (show all 10135)
# Name Status NCT ID Phase Drugs
1 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Unknown status NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
2 Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
3 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
4 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
5 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
6 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
7 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
8 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
9 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
10 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
11 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
12 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
13 Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients Unknown status NCT03043430 Phase 4 Ketamine 100 MG/ML;Midazolam 5 MG/ML
14 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children Unknown status NCT02459509 Phase 4 Dexmedetomidine
15 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
16 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
17 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
18 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
19 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
20 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
21 MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial) Unknown status NCT02856698 Phase 4 Midazolam;Morphine
22 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
23 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
24 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
25 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
26 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
27 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
28 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
29 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
30 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
31 Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
32 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
33 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
34 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
35 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
36 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
37 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
38 Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia Unknown status NCT02258763 Phase 4 Amoxicillin-Potassium Clavulanate Combination;Placebo
39 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
40 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
41 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
42 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
43 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
44 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
45 Vitamin D Supplementations and Postoperative Pain Unknown status NCT02664857 Phase 4 Vitamin D;Placebo
46 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
47 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
48 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
49 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
50 Pregabalin for Alcohol Dependence Unknown status NCT02205879 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 30 SLC6A4

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

42
Brain, Breast, Testes, Heart, Prostate, Lung, Amygdala

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 13990)
# Title Authors Year
1
The incidence of anxiety symptoms in boys with 47,XXY (Klinefelter syndrome) and the possible impact of timing of diagnosis and hormonal replacement therapy. ( 30637954 )
2019
2
Evaluating the effect of lifestyle education based on peer model on anxiety in patients with acute myocardial infarction. ( 30661058 )
2019
3
Efficacy and feasibility of a humor training for people suffering from depression, anxiety, and adjustment disorder: a randomized controlled trial. ( 30894148 )
2019
4
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. ( 30718541 )
2019
5
Internet gaming disorder in male and female young adults: The role of alexithymia, depression, anxiety and gaming type. ( 30616119 )
2019
6
Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series. ( 30681431 )
2019
7
Death anxiety and psychological distress post-donation in non-directed living kidney donors. ( 30907706 )
2019
8
Effectiveness of mindfulness-based coloring for university students' test anxiety. ( 30908136 )
2019
9
Interactive association between negative emotion regulation and savoring is linked to anxiety symptoms among college students. ( 30908167 )
2019
10
A Randomized Controlled Trial Comparing Learners' Decision-making, Anxiety, and Task Load During a Simulated Airway Crisis Using Two Difficult Airway Aids. ( 30908420 )
2019
11
Microbiota of newborn meconium is associated with maternal anxiety experienced during pregnancy. ( 30908632 )
2019
12
Use of distraction techniques for the management of anxiety and fear in pediatric dental practice: a systematic review of randomized controlled trials. ( 30908775 )
2019
13
Frontal lobe dysfunction as a predictor of depression and anxiety following temporal lobe epilepsy surgery. ( 30909053 )
2019
14
Exposure of low-dose fipronil enantioselectively induced anxiety-like behavior associated with DNA methylation changes in embryonic and larval zebrafish. ( 30909129 )
2019
15
Maternity blues: a risk factor for anhedonia, anxiety, and depression components of Edinburgh Postnatal Depression Scale. ( 30909766 )
2019
16
How badly will I feel if you don't like me?: Social anxiety and predictions of future affect. ( 30911203 )
2019
17
Essential Tremor is not Only a Movement Disorder; Its Relationship with Sleep and Anxiety. ( 30911232 )
2019
18
Plasma Neuropeptide-S Levels in Populations Diagnosed with Generalized Anxiety Disorder: A Controlled Study. ( 30911238 )
2019
19
The effect of early change of skin graft dressing on pain and anxiety among burn patients: a two-group randomized controlled clinical trial. ( 30911431 )
2019
20
Efficacy of a transdiagnostic, video-based online program for reducing depression, anxiety, and suicidal ideation in adults: Protocol for a randomised controlled trial. ( 30911696 )
2019
21
Effect of Sexual Rehabilitation Program on Anxiety, Stress, Depression and Sexual Function among Men with Coronary Artery Disease. ( 30912471 )
2019
22
Personality Trait Interactions in Risk for and Protection against Social Anxiety Symptoms. ( 30912711 )
2019
23
Training Residents in the Early Identification of Anxiety Disorders: Feasibility and Preliminary Efficacy of a Novel Training Program. ( 30913896 )
2019
24
Sustained overexpression of neuropeptide S in the amygdala reduces anxiety-like behavior in rats. ( 30914309 )
2019
25
Impact of Place Identity, Self-Efficacy and Anxiety State on the Relationship Between Coastal Flooding Risk Perception and the Willingness to Cope. ( 30915001 )
2019
26
Listening to music prior to bronchoscopy reduces anxiety - a randomised controlled trial. ( 30915199 )
2019
27
A Psychiatrist with Postoperative Anxiety After Hysterectomy: How Could This Be Fatal? ( 30915266 )
2019
28
A Four-Year Prospective Study of Bullying, Anxiety, and Disordered Eating Behavior Across Early Adolescence. ( 30915621 )
2019
29
Virtual reality-based cognitive behavioural therapy for patients with generalized social anxiety disorder: a pilot study. ( 30915939 )
2019
30
Stock Market Exposure and Anxiety in a Turbulent Market: Evidence From China. ( 30873073 )
2019
31
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. ( 30873251 )
2019
32
Diagnostic validity of the anxiety and depression questions from the Well-Being Process Questionnaire. ( 30873498 )
2019
33
Comparing Scores From Full Length, Short Form, and Adaptive Tests of the Social Interaction Anxiety and Social Phobia Scales. ( 30873852 )
2019
34
Differentiating acute suicidal affective disturbance (ASAD) from anxiety and depression Symptoms: A network analysis. ( 30875677 )
2019
35
Cold treatment as an adjunct to inferior alveolar nerve block may reduce pain and anxiety in patients undergoing endodontic treatment in mandibular molars with symptomatic irreversible pulpitis. ( 30876679 )
2019
36
Non-invasive brain stimulation in generalized anxiety disorder: A systematic review. ( 30876986 )
2019
37
Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. ( 30877025 )
2019
38
Effects of a selanylimidazopyridine on the acute restraint stress-induced depressive- and anxiety-like behaviors and biological changes in mice. ( 30877027 )
2019
39
A Randomized Controlled Trial of Attention Bias Modification Treatment in Youth With Treatment-Resistant Anxiety Disorders. ( 30877049 )
2019
40
Social support buffers against anxiety and depressive symptoms in patients with cancer only if support is wanted: a large sample replication. ( 30877598 )
2019
41
Screening for perinatal anxiety disorders: Room to grow. ( 30877859 )
2019
42
A randomised controlled trial of 'MUMentum postnatal': Internet-delivered cognitive behavioural therapy for anxiety and depression in postpartum women. ( 30877878 )
2019
43
Frontoparietal network abnormalities of gray matter volume and functional connectivity in patients with generalized anxiety disorder. ( 30877889 )
2019
44
Single prolonged stress PTSD model triggers progressive severity of anxiety, altered gene expression in locus coeruleus and hypothalamus and effected sensitivity to NPY. ( 30878321 )
2019
45
Phasic amygdala and BNST activation during the anticipation of temporally unpredictable social observation in social anxiety disorder patients. ( 30878610 )
2019
46
When Discrimination Hurts: The Longitudinal Impact of Increases in Peer Discrimination on Anxiety and Depressive Symptoms in Mexican-origin Youth. ( 30879164 )
2019
47
Content-Specific Interpretation Bias in Children with Varying Levels of Anxiety: The Role of Gender and Age. ( 30879167 )
2019
48
Exploring the relationship between gamma-band activity and maths anxiety. ( 30879431 )
2019
49
The impact of pre-operative telephone support and education on symptoms of anxiety, depression, pain and quality of life post total knee replacement: An exploratory case study. ( 30879955 )
2019
50
Utility of Anxiety or Depression domain of EQ-5D to Define Psychological Distress in Spine Surgery. ( 30880196 )
2019

Variations for Anxiety

ClinVar genetic disease variations for Anxiety:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 USH2A NM_206933.2(USH2A): c.2299delG (p.Glu767Serfs) deletion Pathogenic/Likely pathogenic rs80338903 GRCh37 Chromosome 1, 216420437: 216420437
2 USH2A NM_206933.2(USH2A): c.2299delG (p.Glu767Serfs) deletion Pathogenic/Likely pathogenic rs80338903 GRCh38 Chromosome 1, 216247095: 216247095
3 46;XY;t(6;12)(q14;q24);20p+dn complex Pathogenic
4 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic
5 46;XY;t(2;6)(q33;q21)dn Translocation Pathogenic
6 46;XY;t(1;2)(p34.2;q35)dn Translocation Pathogenic
7 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh37 Chromosome 11, 118963865: 118963865
8 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh38 Chromosome 11, 119093155: 119093155
9 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic rs1555350397 GRCh38 Chromosome 14, 56804268: 56804270
10 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic rs1555350397 GRCh37 Chromosome 14, 57270986: 57270988
11 ADAR NM_001193495.2(ADAR): c.761C> A (p.Ala254Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 1, 154571017: 154571017
12 ADAR NM_001193495.2(ADAR): c.761C> A (p.Ala254Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 1, 154598541: 154598541
13 USH2A NM_206933.3(USH2A): c.5003G> T (p.Gly1668Val) single nucleotide variant Uncertain significance GRCh37 Chromosome 1, 216258204: 216258204
14 USH2A NM_206933.3(USH2A): c.5003G> T (p.Gly1668Val) single nucleotide variant Uncertain significance GRCh38 Chromosome 1, 216084862: 216084862
15 MYH8 NM_002472.3(MYH8): c.5743A> G (p.Ile1915Val) single nucleotide variant Uncertain significance GRCh37 Chromosome 17, 10293842: 10293842
16 MYH8 NM_002472.3(MYH8): c.5743A> G (p.Ile1915Val) single nucleotide variant Uncertain significance GRCh38 Chromosome 17, 10390525: 10390525

Copy number variations for Anxiety from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety

Search GEO for disease gene expression data for Anxiety.

Pathways for Anxiety